Department of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY, USA.
Paediatric Critical Care Unit, The Royal London Hospital, London, United Kingdom.
Curr Med Res Opin. 2021 May;37(5):711-718. doi: 10.1080/03007995.2021.1893677. Epub 2021 Mar 8.
Postoperative nausea and vomiting (PONV) is a common complication following surgery, and may be one of the most distressing parts of the surgical journey. With combination pharmacological therapy recommended for PONV prophylaxis, this systematic review and meta-analysis evaluates whether perioperative palonosetron and dexamethasone is more efficacious than palonosetron administered alone.
We searched CENTRAL; EMBASE; CINAHL; Google Scholar; Web of Science citation index; the US clinical trials register; UK clinical trials register; Australia and New Zealand Clinical trials register; and conference abstracts for major anaesthesia conferences in the last three years.We included randomized controlled trials that compared adult patients undergoing surgery who received palonosetron and dexamethasone, against those who received palonosetron.
A total of 12 studies (1152 patients) were included. Medium-grade evidence showed that the palonosetron and dexamethasone combination significantly reduced 24-hour rescue anti-emetic requirement (RR: 0.59, 95% confidence interval (CI): 0.41-0.86). There was however no significant difference in the 6-hour (RR: 0.82, 95% CI: 0.61-1.09) and 24-hour PONV incidences (RR: 0.60, 95% CI: 0.33-1.10). Similarly, PONV incidences after 24 h did not differ between groups (RR:0.82, 95% CI: 0.59-1.14). Headache and dizziness were the most common side-effects reported.
Combination prophylaxis with palonosetron and dexamethasone reduces post-operative anti-emetic requirement, although is not associated with a significant difference in PONV. There was considerable heterogeneity in the studies, and trial sequential analysis indicates that further studies are needed to strengthen the clinical evidence.
术后恶心和呕吐(PONV)是手术后常见的并发症,可能是手术过程中最痛苦的部分之一。由于推荐联合使用药物进行 PONV 预防,本系统评价和荟萃分析评估围手术期给予帕洛诺司琼和地塞米松是否比单独给予帕洛诺司琼更有效。
我们检索了 CENTRAL、EMBASE、CINAHL、Google Scholar、Web of Science 引文索引、美国临床试验注册处、英国临床试验注册处、澳大利亚和新西兰临床试验注册处以及过去三年主要麻醉会议的会议摘要。我们纳入了比较接受帕洛诺司琼和地塞米松治疗的成年手术患者与接受帕洛诺司琼治疗的患者的随机对照试验。
共纳入 12 项研究(1152 名患者)。中等质量证据表明,帕洛诺司琼和地塞米松联合使用可显著减少 24 小时解救性止吐药的需求(RR:0.59,95%置信区间(CI):0.41-0.86)。然而,在 6 小时(RR:0.82,95% CI:0.61-1.09)和 24 小时 PONV 发生率(RR:0.60,95% CI:0.33-1.10)方面,两组之间无显著差异。同样,24 小时后 PONV 发生率在两组之间也没有差异(RR:0.82,95% CI:0.59-1.14)。最常见的不良反应是头痛和头晕。
帕洛诺司琼和地塞米松联合预防可减少术后止吐药的需求,但与 PONV 发生率无显著差异。研究之间存在相当大的异质性,试验序贯分析表明需要进一步研究以加强临床证据。